BACKGROUND: Women with a BRCA1/BRCA2 mutation experience significant challenges. These include decision-making regarding surgical options and notification to offspring and family, along with a sense of isolation, which may lead to psychological and emotional distress. The current study developed, standardized, and conducted preliminary testing of a supportive-expressive group therapy intervention designed to address these challenges. METHODS:Seventy women with a BRCA1/BRCA2 mutation recruited from familial cancer risk clinics participated in 12 sessions ofsupportive-expressive group therapy that lasted 6 months. Before and after measures of psychosocial functioning, knowledge, and surveillance/surgery activities were completed. RESULTS:Sixty-seven women completed the intervention. Significant improvements were observed in psychosocial functioning: cancer worries (P = 0.005), anxiety (P = 0.033), and depression (P = 0.015). Knowledge level and surveillance levels were high at baseline and there were no significant changes postintervention. A significant number of women made decisions concerning prophylactic surgery (oophorectomy/mastectomy) during and after the intervention. CONCLUSIONS: The feasibility of a supportive-expressive group for BRCA1/BRCA2 mutation carriers was demonstrated. Findings from the study are consistent with an effective intervention. However, further research is required using a randomized controlled study design. (c) 2004 American Cancer Society
RCT Entities:
BACKGROUND:Women with a BRCA1/BRCA2 mutation experience significant challenges. These include decision-making regarding surgical options and notification to offspring and family, along with a sense of isolation, which may lead to psychological and emotional distress. The current study developed, standardized, and conducted preliminary testing of a supportive-expressive group therapy intervention designed to address these challenges. METHODS: Seventy women with a BRCA1/BRCA2 mutation recruited from familial cancer risk clinics participated in 12 sessions of supportive-expressive group therapy that lasted 6 months. Before and after measures of psychosocial functioning, knowledge, and surveillance/surgery activities were completed. RESULTS: Sixty-seven women completed the intervention. Significant improvements were observed in psychosocial functioning: cancer worries (P = 0.005), anxiety (P = 0.033), and depression (P = 0.015). Knowledge level and surveillance levels were high at baseline and there were no significant changes postintervention. A significant number of women made decisions concerning prophylactic surgery (oophorectomy/mastectomy) during and after the intervention. CONCLUSIONS: The feasibility of a supportive-expressive group for BRCA1/BRCA2 mutation carriers was demonstrated. Findings from the study are consistent with an effective intervention. However, further research is required using a randomized controlled study design. (c) 2004 American Cancer Society
Authors: Marina J Corines; Jada G Hamilton; Emily Glogowski; Chris A Anrig; Rachael Goldberg; Kate Niehaus; Erin Salo-Mullen; Megan Harlan; Margaret R Sheehan; Magan Trottier; Asad Ahsraf; Christina Tran; Lauren Jacobs; Rohini Rau-Murthy; Anne G Lincoln; Mark E Robson; Jose G Guillem; Arnold J Markowitz; Kenneth Offit; Zsofia K Stadler Journal: J Genet Couns Date: 2016-10-12 Impact factor: 2.537
Authors: Gregory Costain; Mary Jane Esplen; Brenda Toner; Kathleen A Hodgkinson; Anne S Bassett Journal: Schizophr Bull Date: 2012-10-27 Impact factor: 9.306
Authors: Bonnie A McGregor; Emily D Dolan; Karly M Murphy; Timothy S Sannes; Krista B Highland; Denise L Albano; Alison A Ward; Anna M Charbonneau; Mary W Redman; Rachel M Ceballos Journal: Ann Behav Med Date: 2015-12
Authors: B Meiser; V F Quinn; M Gleeson; J Kirk; K M Tucker; B Rahman; C Saunders; K J Watts; M Peate; E Geelhoed; K Barlow-Stewart; M Field; M Harris; Y C Antill; G Mitchell Journal: Eur J Hum Genet Date: 2016-06-22 Impact factor: 4.246